SlideShare une entreprise Scribd logo
1  sur  65
Department of Surgery, University Medical Center Groningen Staging of rectal cancer as an example in oncology Theo Wiggers Cascais, Portugal  Sunday February 13 th ,2011
Staging of rectal cancer Aim and limitations of the workshop ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Elements in  the workshop
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],TNM=pTNM Stage 0:  Tis, N0, M0 Stage I:  T1-T2, N0, M0 Stage IIA: T3, N0, M0 Stage IIB: T4, N0, M0 Stage IIIA: T1-T2, N1, M0 Stage IIIB: T3-T4, N1, M0 Stage IIIC: Any T, N2, M0 Stage IV:  Any T, Any N, M1   TNM  definitions  AJCC 6 th  manual 2002  Dukes
S ystematic review(1):  Preoperative staging of rectal cancer   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Kwok et al Int J Colorectal Dis 2000
S ystematic review(2):  Preoperative staging of rectal cancer   ,[object Object],[object Object],Bipat et al Radiology 2004
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Keep in mind Literature and staging of rectal cancer
Treatment modalities ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Treatment modalities
Discriminating elements ,[object Object],[object Object],[object Object],[object Object],[object Object]
Discriminating elements   Pathological Lymph Nodes ,[object Object],[object Object],[object Object]
Lymph nodes within the mesorectum ,[object Object],[object Object],[object Object],[object Object],Stage I Stage II Stage III Stage VI
Lymph nodes in relation to the endopelvic fascia ,[object Object],[object Object],[object Object],[object Object]
Lymph nodes outside the primary resection field ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Canessa, Dis Col Rect 2004;47:297-303 Data from Japan: metastases in 8-23 %
Pathological lymph nodes outside the endopelvic fascia
Modern staging for large tumors =from the outside cTNM  T1 T2 T3 T3 T4 Primary resectable Locally Advanced T3 T3 T4
Three possibilities “ resectable”, “ operable”, “fixed” , “ tethered”, “I can get it out” ,[object Object],[object Object],[object Object]
The ideal world
The expert ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Simunovic et al; Br J Surg 2003
Real life ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Brown; Br J Cancer 2004
Imaging modalities ,[object Object],[object Object],[object Object],[object Object],[object Object]
Possibilities
Layers of the bowel wall EUS Accuracy: EUS: 87% CT: 73% MRI: 82% Kwok et al Int J Colorectal Dis 2000
Bowel wall layers CT Not well visible CT: 73% EUS: 87% MRI: 82% Kwok et al Int J Colorectal Dis 2000
Bowel wall layers  MRI
Bowel wall layers MRI ,[object Object],[object Object],[object Object],Kwok et al Int J Colorectal Dis 2000
Bowel wall layers  PET-FDG Not visible
Endopelvic fascia EUS Not visible
  Endopelvic fascia CT ,[object Object],[object Object],[object Object],[object Object],[object Object],Wolberink Dis Colon Rectum 2009 EUS: 87% CT: 73% MRI: 82%
  Endopelvic fascia MRI
MRI  & CRM: a meta-analysis ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Lahaye, Beets, vd Velde, Beets-Tan. Semin US, CT & MRI 2005
Endopelvic fascia PET/CT Not visible
Lymph node metastases  EUS ,[object Object],[object Object],[object Object],Kwok et al Int J Colorectal Dis 2000
  Lymph node metastases  CT ,[object Object],[object Object],[object Object],Kwok et al Int J Colorectal Dis 2000
  Lymph node metastases  MRI ,[object Object],[object Object],[object Object],Kwok et al Int J Colorectal Dis 2000
Lymph node metastases  PET-FDG Sometimes visible
In growth other organs  EUS Prostate, vagina, Pelvic floor
  In growth other organs  CT
In growth other organs  MRI
In growth other organs  PET-FDG Not visible
Distant metastases  EUS
  Distant metastases  CT ,[object Object],[object Object],[object Object],Chest CT 200 patients 7% pulmonary metastases 25% intermediate lesions   Grossmann 2009
Distant metastases  MRI
Distant metastases  PET-FDG
CRC: CT versus FDG PET Wiering Ann Surg Oncol 2007; 14:818–826
Summary
EUS ,[object Object],[object Object],[object Object],[object Object],[object Object],New possibilities New contrast agents Three dimensional EUS
CT ,[object Object],[object Object],[object Object],[object Object],[object Object],New possibilities Multidetector, Reconstructions in all directions
MRI ,[object Object],[object Object],[object Object],[object Object],[object Object],New possibilities “ Whole body MRI” New contrast agents Assessment of the MRF after neoadjuvant treatment
USPIO
USPIO MRI MRI
USPIO ,[object Object],[object Object],[object Object],Lahaye et al. Radiology 2008; 246: 804-811
Liver metastases Bipat et al. Radiology 2005; 237:123–131
MRF assessment after chemoradiation ,[object Object],[object Object],[object Object],[object Object],Vliegen et al. Radiology 2008; 246:454–462
Response on MRI Department of Surgery, University Medical Center Groningen preradiation postradiation 0/26 (0%) MRF+
Response on MRI Department of Surgery, University Medical Center Groningen postradiation preradiation 21/53 (40%) MRF+
Post CRT involvement of CRM ,[object Object],[object Object],[object Object],[object Object],[object Object],Department of Surgery, University Medical Center Groningen MERCURY study group, BMJ 2006 Vliegen, et al, Radiology 2008
PET/CT ,[object Object],[object Object],[object Object],[object Object],New possibilities Better fusion options Response after chemoradiation
 
FDG PET: POLEM study ,[object Object],[object Object],[object Object],[object Object],[object Object],Oyen et al. Unpublished data
CRC FDG PET chemotherapy response de Geus-Oei. Ann Oncol 2008; 19: 348–352, 2008
Response on PET ,[object Object],[object Object],Department of Surgery, University Medical Center Groningen before after Vliegen et al. submitted
From clinical to imaging=fusing of disciplines
“ Take home message” ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Similaire à MCC 2011 - Slide 2

Treatment of Muscle Invasive Bladder Carcinoma
Treatment of Muscle Invasive Bladder Carcinoma Treatment of Muscle Invasive Bladder Carcinoma
Treatment of Muscle Invasive Bladder Carcinoma Dr.Bhavin Vadodariya
 
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...European School of Oncology
 
Petct In Gynecologic Cancer
Petct In Gynecologic CancerPetct In Gynecologic Cancer
Petct In Gynecologic Cancerfondas vakalis
 
Surgical persrective in lung cancer
Surgical persrective in lung cancerSurgical persrective in lung cancer
Surgical persrective in lung cancerHarilal Nambiar
 
Rectal MRI .pptx
Rectal MRI .pptxRectal MRI .pptx
Rectal MRI .pptxrojelio101
 
The surgical management of gastroesophageal cancer
The surgical management of gastroesophageal cancerThe surgical management of gastroesophageal cancer
The surgical management of gastroesophageal cancerforegutsurgeon
 
RT for lung cancer at SMC
RT for lung cancer at SMCRT for lung cancer at SMC
RT for lung cancer at SMCYong Chan Ahn
 
Staging and Diagnostic approach of rectal cancer
 Staging and Diagnostic approach  of rectal cancer Staging and Diagnostic approach  of rectal cancer
Staging and Diagnostic approach of rectal cancerDr.Bhavin Vadodariya
 
Organ Preservation Surgery For Laryngeal Cancer
Organ Preservation Surgery For Laryngeal CancerOrgan Preservation Surgery For Laryngeal Cancer
Organ Preservation Surgery For Laryngeal Cancerfondas vakalis
 
cancer staging.pptx
cancer staging.pptxcancer staging.pptx
cancer staging.pptxMona Quenawy
 
Managememt of Carcinoma Nasopharynx
Managememt  of Carcinoma NasopharynxManagememt  of Carcinoma Nasopharynx
Managememt of Carcinoma NasopharynxIsha Jaiswal
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationalefondas vakalis
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationalefondas vakalis
 
11.Lungcancer
11.Lungcancer11.Lungcancer
11.Lungcancerghalan
 

Similaire à MCC 2011 - Slide 2 (20)

Rectal cancer
Rectal cancerRectal cancer
Rectal cancer
 
Treatment of Muscle Invasive Bladder Carcinoma
Treatment of Muscle Invasive Bladder Carcinoma Treatment of Muscle Invasive Bladder Carcinoma
Treatment of Muscle Invasive Bladder Carcinoma
 
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
Endoscopy in Gastrointestinal Oncology - Slide 5 - R. Rosati - Esophageal can...
 
Petct In Gynecologic Cancer
Petct In Gynecologic CancerPetct In Gynecologic Cancer
Petct In Gynecologic Cancer
 
Surgical persrective in lung cancer
Surgical persrective in lung cancerSurgical persrective in lung cancer
Surgical persrective in lung cancer
 
Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)
 
Jc1
Jc1Jc1
Jc1
 
Rectal MRI .pptx
Rectal MRI .pptxRectal MRI .pptx
Rectal MRI .pptx
 
Oesophageal carcinoma
Oesophageal carcinomaOesophageal carcinoma
Oesophageal carcinoma
 
MCC 2011 - Slide 26
MCC 2011 - Slide 26MCC 2011 - Slide 26
MCC 2011 - Slide 26
 
The surgical management of gastroesophageal cancer
The surgical management of gastroesophageal cancerThe surgical management of gastroesophageal cancer
The surgical management of gastroesophageal cancer
 
RT for lung cancer at SMC
RT for lung cancer at SMCRT for lung cancer at SMC
RT for lung cancer at SMC
 
Staging and Diagnostic approach of rectal cancer
 Staging and Diagnostic approach  of rectal cancer Staging and Diagnostic approach  of rectal cancer
Staging and Diagnostic approach of rectal cancer
 
Organ Preservation Surgery For Laryngeal Cancer
Organ Preservation Surgery For Laryngeal CancerOrgan Preservation Surgery For Laryngeal Cancer
Organ Preservation Surgery For Laryngeal Cancer
 
MCC 2011 - Slide 28
MCC 2011 - Slide 28MCC 2011 - Slide 28
MCC 2011 - Slide 28
 
cancer staging.pptx
cancer staging.pptxcancer staging.pptx
cancer staging.pptx
 
Managememt of Carcinoma Nasopharynx
Managememt  of Carcinoma NasopharynxManagememt  of Carcinoma Nasopharynx
Managememt of Carcinoma Nasopharynx
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationale
 
Renal Cancers Rationale
Renal Cancers RationaleRenal Cancers Rationale
Renal Cancers Rationale
 
11.Lungcancer
11.Lungcancer11.Lungcancer
11.Lungcancer
 

Plus de European School of Oncology

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasEuropean School of Oncology
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasEuropean School of Oncology
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineEuropean School of Oncology
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artEuropean School of Oncology
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer European School of Oncology
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerEuropean School of Oncology
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artEuropean School of Oncology
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artEuropean School of Oncology
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
 

Plus de European School of Oncology (20)

ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
 
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
 
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
 
W. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - GuidelinesW. Hassen - Bladder cancer - Guidelines
W. Hassen - Bladder cancer - Guidelines
 
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomasA. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
 
H. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the artH. Khaled - Bladder cancer - State of the art
H. Khaled - Bladder cancer - State of the art
 
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomasA. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
 
1 azim
1 azim1 azim
1 azim
 
H. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the artH. Azim - Lymphomas - State of the art
H. Azim - Lymphomas - State of the art
 
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccineS. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
 
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
 
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the artJ.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
 
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
 
V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art V. Kesic - Cervical cancer - State of the art
V. Kesic - Cervical cancer - State of the art
 
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
 
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancerN. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
 
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the artS. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
 
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
 
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the artG. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
 
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
 

MCC 2011 - Slide 2

Notes de l'éditeur

  1. The size of a pinhead
  2. Purpose: To prospectively determine diagnostic performance of predictive criteria for nodal staging with ultrasmall superparamagnetic iron oxide (USPIO)–enhanced magnetic resonance (MR) imaging in primary rectal cancer patients, with histopathologic findings as reference standard. Materials and Methods: Institutional review board approval and informed consent were obtained. Twenty-eight rectal cancer patients (18 men, 10 women; mean age, 68 years) underwent USPIOenhanced MR. Two observers with different experience evaluated each node on three-dimensional T2*-weighted images for border irregularity, short- and long-axis diameter, and estimated percentage (30%, 30%–50%, or 50%) of white region within the node. Ratio of measured surface area of white region within the node to measured surface area of total node (ratioA) was calculated. Signal intensity (SI) of gluteus muscle (SIGM), total node (SITN), and white (SIWR) and dark (SIDR) regions within the node were used to calculate SITN/SIGM and SIWR/SIDR ratios. Lesion-by-lesion, receiver operating characteristic curve, and interobserver agreement analyses were performed. The most accurate and practical criterion was evaluated by observer 3. Results: In 28 patients, 236 lymph nodes were examined. Area under the receiver operating characteristic curve (AUC) of estimated percentage of white region and ratioA were 0.96 and 0.99 (observer 1) and 0.95 and 0.97 (observer 2), respectively. AUC of estimated percentage criterion for observer 3 was 0.96. AUC of border, short- and long-axis diameter, and SITN/SIGM and SIWR/SIDR ratios were 0.65, 0.75, 0.79, 0.85, and 0.75 (observer 1) and 0.58, 0.75, 0.79, 0.89, and 0.79 (observer 2), respectively. Interobserver agreement ( value) for estimated white region between observers 1 and 2, 1 and 3, and 2 and 3 were 0.77, 0.79, and 0.84, respectively. For observers 1 and 2, value for border was 0.28. For observers 1 and 2, intraclass correlation coefficient for short- and long-axis diameters, ratioA, and SITN/SIGM and SIWR/SIDR ratios were 0.91, 0.96, 0.91, 0.72, and 0.92, respectively. Conclusion: Estimated percentage of white region and measured ratioA are the most accurate criteria for predicting malignant nodes with USPIO-enhanced MR imaging; the first criterion is the most practical.
  3. Purpose: To retrospectively assess sensitivity and specificity of magnetic resonance (MR) imaging after chemotherapy and radiation therapy for predicting tumor invasion of the mesorectal fascia (MRF) in locally advanced primary rectal cancer, by using results of histologic examination and surgery as the reference standard, and to determine morphologic MR imaging criteria for MRF invasion. Materials and Methods: The Ethical Committee of University Hospital Maastricht approved this study and waived informed consent. Two observers independently scored postchemoradiation MR images in 64 patients with rectal cancer (38 male [mean age, 60 years] and 26 female [mean age, 64 years] patients) for MRF tumor invasion with a confidence level scoring system defined by subjective criteria. In a subsequent consensus reading session, morphologic MR criteria for invasion were defined by comparing morphologic changes with histologic findings. These criteria were evaluated and compared with the subjective criteria by comparing areas under the receiver operating characteristic curves (AUCs). Results: AUCs of postchemoradiation MR imaging for predicting MRF tumor invasion were 0.81 and 0.82 for observers 1 and 2, respectively. The following four types of morphologic tissue patterns at MR imaging were associated with whether or not MRF invasion was present at histologic examination: (a) development of fat pad larger than 2 mm (seen in no quadrants with and in four quadrants without invasion), (b) development or persistence of spiculations (seen in no quadrants with and in 22 quadrants without invasion), (c) development of diffuse hypointense “ fibrotic” tissue (seen in 21 quadrants with and in 32 quadrants without invasion), and (d) persistence of diffuse isoor hyperintense tissue (seen in 19 quadrants with and in two quadrants without invasion). AUC of postchemoradiation MR imaging for predicting MRF invasion on the basis of morphologic criteria was 0.80. There was no significant difference between the performance of subjective and morphologic criteria ( P .73–.76). Conclusion: Postchemoradiation MR imaging findings have moderate accuracy for predicting tumor invasion of the MRF related to the limitation in differentiating between diffuse “fibrotic” tissue with and that without small tumor foci. Specific other types of morphologic patterns atMRimaging can highly predict a tumor-free or invaded MRF.
  4. Location of metastases Liver 43 Lung 15 (Retro)peritoneal lymph nodes 4 Bone 2